Chemical epigenetics to assess the role of HDAC1-3 inhibition in macrophage pro-inflammatory gene expression by Ourailidou, Maria E. et al.
  
 University of Groningen
Chemical epigenetics to assess the role of HDAC1-3 inhibition in macrophage pro-
inflammatory gene expression






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Ourailidou, M. E., Leus, N. G. J., Krist, K., Lenoci, A., Mai, A., & Dekker, F. J. (2016). Chemical epigenetics
to assess the role of HDAC1-3 inhibition in macrophage pro-inflammatory gene expression.
MedChemCommun, 7(11), 2184-2190. https://doi.org/10.1039/c6md00375c
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Cite this: Med. Chem. Commun.,
2016, 7, 2184
Received 7th July 2016,
Accepted 2nd September 2016
DOI: 10.1039/c6md00375c
www.rsc.org/medchemcomm
Chemical epigenetics to assess the role of HDAC1–3
inhibition in macrophage pro-inflammatory gene
expression†‡
Maria E. Ourailidou,a Niek G. J. Leus,a Kim Krist,a Alessia Lenoci,b
Antonello Mai*bc and Frank J. Dekker*a
Histone deacetylases (HDACs) have been used as pharmacological targets for the treatment of various dis-
eases. Some non-selective HDAC inhibitors (HDACi) have been clinically-used as therapeutic agents for
treatment of hematological cancers but their cytotoxic side effects are an important downside. The discov-
ery of more selective inhibitors has certified the involvement of individual HDACs in pathological processes
but the elucidation of the role of specific family members in inflammatory responses still remains a chal-
lenge. Here, we report the development of closely related, structural analogues of the clinically-used
HDACi Entinostat via a chemical epigenetic approach. Three compounds were designed and synthesized
in which the cap moiety of Entinostat was replaced by an azobenzene group that is either para, meta or
ortho substituted. The compounds were then evaluated for selectivity towards HDACs 1–3 and their effect
on pro-inflammatory gene expression in macrophages. One analogue, compound 4, lacked selectivity and
demonstrated inhibition of NF-κB reporter gene activity and pro-inflammatory gene expression in
RAW264.7 macrophages, thus indicating that there is a delicate balance between the selectivity of HDACi
over specific family members and their pro- or anti-inflammatory effects.
Introduction
Reversible lysine acetylation has been extensively proven to
play a critical role in epigenetic regulation of gene
expression.1–5 Lysine acetylation is catalyzed by histone
acetyltransferases (HATs) (writers), leading to transcriptionally
active chromatin, while the reverse process is catalyzed by his-
tone deacetylases (HDACs) (erasers) resulting in condensed
chromatin and transcriptional silencing. Over the past de-
cades, eighteen mammalian HDACs have been identified and
divided into four classes (I–IV) according to their sequence
homology to yeast orthologs.6 Among them, class I,
containing the zinc-dependent HDACs 1–3 and 8, is crucial
for normal cell survival, homeostasis, proliferation and gene
expression.7 Consequently, mounting evidence points to a
link between abnormal HDAC activity and inflammatory8 and
neurological diseases,9 tumorigenesis,9,10 and metabolic
disorders.11
There is a tremendously increasing interest in the develop-
ment of HDAC inhibitors (HDACi) as potential therapeutic
agents for several pathological conditions. To date, a wide va-
riety of small molecules has been reported to target HDACs,
with differences in their structure, potency, selectivity and,
thus, pharmacological effects.7,12 However, a limited number
has reached clinical trials and has been approved for medical
use, mainly for treatment of cancer patients.13,14 The toxicity
of the currently available chemotherapeutic agents hamper
their further applications. Nevertheless, more selective HDAC
inhibitors such as Entinostat targeting only HDAC1–3 is less
toxic in clinical trials compared to the non-selective HDAC in-
hibitors thus providing a perspective towards clinical applica-
tions of these inhibitors.15 Recently, significant efforts in the
field of medicinal chemistry have led to the discovery of more
selective inhibitors9,16–21 that have shed some light on the
role of individual HDACs in specific diseases. Yet, the impor-
tant question that remains to be answered is whether inhibi-
tion of specific HDAC family members enables achievement
of the desired biological effects. In order to address this issue
it is imperative to develop novel methods to investigate the in-
hibition pattern needed for each disease model.
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Our interest lies in the better understanding of the role of
class I HDACs in inflammatory signaling. It is known that
HDACs influence the activation of NF-κB pathway, a key media-
tor in inflammatory diseases like COPD and asthma.22,23 Studies
indicate that acetylations of specific lysine residues of the NF-κB
p65 transcription factor affect its transcriptional capacity, dura-
tion of action and DNA binding.22,24 The alterations observed in
NF-κB-mediated gene expression after treatment with HDACi
confirm a deacetylation-dependent mechanism of activation.25–27
Several groups have reported the pivotal role of HDACs 1–3 in in-
flammatory responses, such as Schwann cell myelination, intesti-
nal epithelial cell homeostasis and allergic reaction.28–32 Re-
cently, we explored the function of HDACs 1–3 in inflammatory
gene expression in LPS/IFNγ-stimulated murine macrophages by
si-RNA-mediated downregulation.26 Our data suggested a pro-
inflammatory role for HDAC1 and 3. Furthermore, selective
pharmacological HDAC3 inhibition by RGFP966 demonstrated
an attenuation of pro-inflammatory signals in models for inflam-
matory lung diseases. In another study, HDACi highly potent
against HDAC3 and/or HDAC6 have been shown to downregu-
late mRNA expression of pro-inflammatory cytokines (IL-1β
and IL-6) and to promote the transcription of IL-10 gene in
KB31, C2C12, and 3T3-J2 cell lines, without affecting the cell
viability.33 Yet, further optimization is required in the devel-
opment of novel HDACi, mainly against HDAC1 and 3, as
anti-inflammatory therapeutics in order to obtain a clearer
picture on which HDAC family member to target.
A very promising approach towards this purpose is the use
of chemical epigenetic tools, where a parental clinically avail-
able agent is slightly modified to generate closely related in-
hibitors with a different selectivity profile among biological
family members. This approach aims at the fine-tuning of
the selectivity of inhibitors over specific family members with
respect to their pharmacological effects.34 Therefore, we set
out to design closely related analogues of Entinostat (MS-
275), an ortho-aminoanilide containing HDAC1–3 inhibitor
with proven therapeutic properties, currently undergoing
clinical trials for treatment of various cancers.35 These ana-
logues embody isomeric ortho-aminoanilide-type HDAC inhib-
itors with an azobenzene cap. Inhibition and kinetic studies
against class I HDACs were performed in order to evaluate
their potency and binding kinetic parameters. Next, we tested
the effects of the inhibitors on transcriptional activity and
intracellular localization of NF-κB p65 as well as inflamma-
tory gene expression in LPS/IFNγ-stimulated murine macro-
phages. Interestingly, one analogue (compound 4, para
isomer) demonstrated anti-inflammatory characteristics pro-




For our purposes, we chose Entinostat as a starting point to
design novel HDACi with refined characteristics. The ortho-
aminoanilide group, that serves for zinc binding, is advanta-
geous compared to the hydroxamic acid moiety (like
suberanilohydroxamic acid, SAHA, pan-HDACi) as it assures
for selective inhibition among class I HDACs 1–3, reducing
cytotoxicity.36–38 Our modifications were limited to the cap re-
gion of Entinostat, where an azobenzene group was intro-
duced to a para, meta and ortho position with respect to the
amine group of the connection unit of the parental inhibitor
(compounds 4, 7, and 9 respectively, Fig. 1). Azobenzenes are
often used in photopharmacology as photoswitches that al-
low for two isomeric forms, preferably the cis being more po-
tent than the trans analogue.39–41 Previously, we developed
successfully SAHA photoswitchable derivatives as potential
antitumor agents.42 Our data demonstrated that substitution
of the cap of the original drug with an azobenzene group in
the para, meta and ortho position led to notable differences
in terms of potency of the trans form (meta and ortho isomers
more potent than para). Additionally, para and ortho trans
isomers provided an improved selectivity towards HDACs 1
and 3. These findings encouraged us to employ the same
structural alterations in Entinostat in an attempt to improve
potency and specificity among HDACs 1–3 and gain useful in-
formation on the selectivity profile required to inhibit pro-
inflammatory gene expression in macrophages.
Synthesis
The starting materials were synthesized as described previ-
ously.42 Two synthetic routes were followed for the produc-
tion of the Entinostat analogues (see ESI‡). Compound 4 was
synthesized by a reductive amination reaction between
methyl-4-formylbenzoate and (E)-4-(phenyldiazenyl)aniline.
Subsequent hydrolysis to the corresponding ester allowed
for coupling to the mono tert-butyloxycarbonyl-protected
2-aminoaniline. Boc deprotection using a solution of 4 N HCl
afforded compound 4. As for compounds 7 and 9, the peptide
coupling between the mono Boc-protected 2-aminoaniline
Fig. 1 Design of structural analogues of Entinostat. An azobenzene
moiety was introduced into the CAP region in para (4), meta (7) and
ortho (9) position in respect to the amine group of the CU of
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and 4-formylbenzoic acid was performed first followed by re-
ductive amination using the corresponding (phenyldiazenyl)
aniline. For compound 7, the deprotection of Boc group was
performed as for compound 4, while the same conditions led
to benzyl cleavage due the basic nature of the amino group
at the ortho position of the azobenzene in compound 9. In
this case, milder acidic conditions were used by employing
trifluoroacetic acid.
IC50 values reveal limited selectivity among HDACs 1–3
The resulting collection of structurally related HDACi was
tested for HDAC inhibition via an assay based on the mea-
surement of the deacetylation of a pro-fluorogenic sub-
strate.42 Prior to testing, the stock solutions of the inhibitors
(10 mM in DMSO) were heated at 60 °C for 10 min to ensure
occurrence of the azobenzene in its trans isomeric form. Vari-
ous concentrations of each inhibitor were incubated with
HDAC1, 2, 3 or 8 in presence of the substrate Boc-LysĲAc)-
AMC at room temperature. After one hour, the reaction was
stopped by the addition of SAHA and trypsin to cleave the
deacetylated lysine, resulting in the release of fluorescent
7-amino-4-methylcoumarin (AMC). As expected for ortho-
aminoanilide-type inhibitors, no inhibition was observed
against HDAC8 at concentrations up to 50 μM. It is known
that Entinostat inhibits HDACs 1, 2 and 3 with a potency of
0.18, 1.2 and 2.3 μM correspondigly.43 The IC50 values of our
isomeric set of compounds were found to be in the low μM
range with no meaningful differences among individual fam-
ily members (see ESI‡ Fig. S1). We then set out to perform ki-
netic studies in order to determine the affinity rate constant
(Ki) values, known to be more representative for the inhibi-
tory potencies.
Binding kinetic analysis reaffirms a non-family member-
selective profile
Previous studies have shown that enzyme binding kinetics
are more informative on the selectivity and behavior of the
inhibitors inside the biological targets.44 Therefore, we ex-
panded our investigations with determination of the enzyme
kinetics on HDAC1, 2 and 3. There is strong evidence that
ortho-aminoanilides are slow, tight-binding inhibitors, follow-
ing the mechanism of enzyme inhibition.34,45 In contrast to
hydroxamate-based inhibitors, they act via a slow on/slow off
binding; they are characterized by low association rate con-
stants (kon) and form a tight complex with the enzyme (EI),
exhibiting long residence times. In order to determine the ki-
netic parameters of each inhibitor, Lys-C peptidase was used
as a developer instead of trypsin as described by Chou et al.
to prevent enzyme degradation.46 Moreover, the deacetylation
reaction was not stopped by the addition of SAHA but HDAC
activity was monitored over time to generate progress curves
allowing for the investigation of the rate constants.46
According to a previously reported protocol, the measure-
ment of the association rate constants (kon) involved the incu-
bation of HDACs 1–3 with different concentrations of the
inhibitors in presence of Lys-C and high amounts of the sub-
strate (5 × KM).
46 The fluorescence was monitored for 60–90
min at room temperature. The progress curves of all the in-
hibitors confirmed a time-dependent mechanism of HDAC
inhibition and a linear relationship between kobs and inhibi-
tor concentration as observed before (Fig. S2,‡ kon values
were calculated as described in the ESI‡ section).46 The off-
rate constants (koff) were determined after 100-fold dilution
of samples containing high concentrations of HDACs 1–3
pre-incubated for 1 h with each inhibitor, and subsequent
measurement of HDAC activity as described above.46
In terms of selectivity among family members, all com-
pounds appeared to bind faster in HDAC1, less fast in
HDAC2 and even slower in HDAC3 (compound 7 presented
similar kon values in HDAC2 and 3) (Fig. 2, ESI‡ Table S1).
More specifically, regarding HDAC1, compounds 4 and 7
were found to bind slightly faster than the reference
Entinostat whereas the observed kon values in HDAC2 were
lower. Compound 9 displayed the smallest kon values in all
HDACs 1–3 (even 3.5× slower than Entinostat in the case of
HDAC3). A certain pattern was also noticed during dissocia-
tion experiments, where we discovered that Entinostat and
its azobenzene analogues are generally released rapidly from
HDAC3, less fast from HDAC1 and remain longer in HDAC2
(compound 7 presented similar koff values in HDAC1 and 3)
(Fig. 2). Compound 4 showed longer residence in HDAC1
and 3 than compounds 7 and 9, whereas the dissociation rate
from HDAC2 was found to be similar for all the developed in-
hibitors. We then used the kon and koff values of the ana-
logues to calculate the affinity rate contants Ki, using the
Fig. 2 Comparison bar graphs of the kinetic values of Entinostat (E)
and its para (4), meta (7) and ortho (9) azobenzene analogues on
HDACs 1–3 expressed in logarithmic scale. The data are presented as
mean values of three independent measurements with their respective
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following equation: Ki = koff/kon (see ESI,‡ Table S2). All com-
pounds exhibited statistically significant differences in their
potencies against HDACs 1 and 2 in comparison to HDAC3,
while stronger inhibition was observed for compound 4.
However, the differences in potencies among family members
are still subtle in order to be further useful to explain any
pharmacological variations. The subtle differences in these
cases are clearly different from the 10-fold preference for
HDAC3 inhibition observed for ortho-aminoanilide type
HDAC inhibitors lacking the phenyl group in the linker
region.46
Compound 4 exhibits anti-inflammatory effects in LPS/IFNγ-
stimulated murine macrophages
Extensive literature has established the connection between
HDACs 1–3 and inflammatory signaling in macrophages.47–49
In order to investigate the effect of 1–3 selective HDAC inhib-
itors in inflammatory pathways, we performed a series of
pharmacological studies in RAW264.7 murine macrophages.
Each time, cells were incubated with the respective inhibitor
for 20 h followed by inflammatory stimulation with LPS and
IFNγ during the last 4 h to ensure activation towards M1
(pro-inflammatory) macrophages.50
Compound 4 attenuates NF-κB p65 transcriptional activ-
ity. Upon stimulation (e.g. by inflammatory cytokines), the
p50–p65 heterodimer is released from the complex with IκBα
and translocated to the nucleus resulting in the upregulation
of the expression of specific genes.22 As mentioned in the in-
troduction, acetylation and, consequently, deacetylation are
of key importance in the regulation of NF-κB p65 transcrip-
tional activity. The latter was assessed using a reporter gene
assay (see ESI‡). First, we explored the cell viability after
treatment with different concentrations of HDACi. Impor-
tantly, compounds 4, 7 and 9 showed no effect on cell viabil-
ity at concentrations up to 50 μM (see ESI‡ Fig. S3). Next to
Fig. 3 Effects of para (4), meta (7) and ortho (9) azobenzene analogues of Entinostat on LPS/IFNγ-induced NF-κB p65 transcriptional activity. RAW
blue cells were treated with the respective HDAC inhibitors at the indicated concentrations for 20 h and stimulated with LPS/IFNγ for the last 4 h
of the experiment. For vehicle treatment, cells were pre-treated with a proportional dilution of the inhibitor solvent DMSO. Data are shown as rep-
resentative data set of 3 independent experiments with the respective standard deviations. *p < 0.05, ***p < 0.001 compared to vehicle-treated
group.
Fig. 4 Effects of para (4), meta (7) and ortho (9) azobenzene
analogues of Entinostat on nuclear translocation profile of NF-kB p65
in RAW264.7 macrophages. After 20 h incubation with 1 μM of the re-
spective inhibitors followed by 1 h LPS/IFNγ stimulation, RAW264.7
macrophages were prepared for immunofluorescence microscopy.
Green signal represents NF-kB p65 protein, while the blue signal visu-
alizes the Hoechst stained nuclei. The presented data set shows repre-
sentative images of 2 independent experiments, original magnification
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this, the stability of the azobenzene-containing inhibitors to-
wards reduction in cellular environment was previously veri-
fied after testing in presence of 10 mM of glutathione.42
RAW264.7 cells were treated with compounds 4, 7 and 9
in a concentration range 1–10 μM. Interestingly, treatment
with para (4) or ortho (9) isomers resulted in inhibition of
NF-κB p65 transcriptional activity with the highest effect ob-
served at 10 μM (up to 50% reduction, Fig. 3). On the con-
trary, a robust activation of NF-κB p65 was found in case of
10 μM of meta derivative (7), while lower concentrations gave
no change.
These findings provided the first indications that struc-
tural modifications and relatively small changes in inhibitory
selectivity among HDACs 1–3 can result in considerable dif-
ferences in pharmacological performance. Yet, considering
that at 10 μM the HDAC activity is mostly inhibited, the dif-
ferences in the biological behavior of the analogues cannot
be entirely attributed to HDAC inhibition as other cellular
targets may also be involved.
Compound 7 increases NF-kB p65 nuclear translocation in
contrast to compounds 4 and 9. Fluorescence microscopy
was used to locate NF-κB p65 in the nucleus of LPS/IFNγ-
stimulated RAW264.7 macrophages (see ESI‡). After proper
staining, NF-κB p65 was shown in green while cell nuclei
were visualized in blue (Fig. 4). Immunofluorescence micros-
copy images were overlaid and compared to vehicle. In our
experiments, compound 7 seemed to enhance the nuclear
translocation of NF-κB p65 (Fig. 4), while in contrast, com-
pounds 4 and 9 did not influence or reduced it. Collectively,
these data are consistent with the studies on the NF-κB tran-
scriptional activity that indicated inhibition for compounds 4
and 9 and activation for 7. Hence, considering the rather
non-selective profile of these inhibitors over HDAC family
members, we suggest that other mechanisms crucial for NF-
kB p65 activity are also affected.
Compound 4 reduces the expression of pro-inflammatory
genes. After cellular LPS/IFNγ-stimulation and treatment with
1, 5 and 10 μM of each Entinostat analogue, we set out to
monitor the expression levels of TNF-α, iNOS, IL-1β, IL-6 and
IL-12b. We found that compound 4 caused a statistically sig-
nificant dose dependent reduction in the expression of TNF-
α and IL-6 (IL-6 reduced by 90% at 10 μM) (Fig. 5). Remark-
ably, compound 4 had no effect on the iNOS expression levels
in contrast to compounds 7 and 9, when used at their highest
concentrations. Notifying, suppression of IL-1β and IL-12b
was demonstrated only after treatment with compound 4,
Fig. 5 Effects of para (4), meta (7) and ortho (9) azobenzene analogues of Entinostat on pro- and anti-inflammatory gene expression in RAW264.7
macrophages. Cells were treated with the respective HDAC inhibitors at the indicated concentrations for 20 h and stimulated with LPS/IFNγ for
the last 4 h of the experiment. Gene expression was analyzed by RT-q-PCR. For vehicle treatment, cells were pre-treated with a proportional dilu-
tion of the inhibitor solvent DMSO. Data represent the target gene expression normalized to the reference gene and are presented as mean values
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however these effects were not statistically significant. Favor-
ably, these data clarify a pronounced anti-inflammatory pro-
file for the para isomer 4 and add to the previously mentioned
scenario that the apparent differences in gene expression can-
not be solely explained via HDAC inhibition but also through
other targets with a key role in inflammatory pathways.
Conclusions
In summary, we developed three structural analogues of the
clinically-used ortho-aminoanilide type HDAC1–3 inhibitor
Entinostat in an attempt to explore the role of class I HDACs
in macrophage pro-inflammatory signaling. The compounds
exhibited small differences in their HDAC inhibitory profile
with a slight preference to HDAC1 and 2. Studies on the ef-
fect of the inhibitors on LPS/IFNγ-induced inflammatory re-
sponses in RAW264.7 macrophages revealed that compounds
4 and 9 impaired NF-κB p65 transcriptional activity and
suppressed NF-κB p65 nuclear translocation, while an in-
crease was observed in case of compound 7. These findings
suggest that, additionally to overall HDAC inhibition, the
designed compounds target other mechanisms that play a
role in transcriptional activity of NF-κB p65. Further investi-
gations of the impact of the analogues on the expression of
pro-inflammatory genes corroborated the anti-inflammatory
profile of compound 4.
Our work supports that a non-selective inhibition of
HDACs 1–3 offers a promising potential towards the desirable
anti-inflammatory characteristics, taking into account that
possible off-target effects may be significant as well. This sets
the stage for further development and exploration of the con-
tribution of HDAC1, 2 and 3 in drug discovery effort aimed at
the development of anti-inflammatory therapeutics based on
the ortho-aminoanilide scaffold. Moreover, we demonstrated
that chemical epigenetics can be employed as a useful strat-
egy in order to fine-tune the family member(s) selectivity with
the ultimate goal to develop inhibitors that possess the de-
sired pharmacological behavior.
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